Article info
PDFPoster Presentations
Public health, health services research and health economics
THU0640 Second line treatment persistence and costs among patients with immune-mediated rheumatic diseases treated with subcutaneous tnf-alpha inhibitors
Citation
THU0640 Second line treatment persistence and costs among patients with immune-mediated rheumatic diseases treated with subcutaneous tnf-alpha inhibitors
Publication history
- First published June 15, 2017.
Online issue publication
January 09, 2022
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© 2017, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions